Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01564706 · ClinicalTrials.gov registry record · Phase 1
A Study of 18F-AV-45 in Healthy Volunteers
A Phase 1 study, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01564706: Completed Phase 1 study, sponsored by Avid Radiopharmaceuticals.
NCT01564706 is a Phase 1 study that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01564706, a Phase 1 study, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study will determine how florbetapir F 18 (18F-AV-45) radioactivity is distributed throughout the body.
Primary Outcome
Radiation dose values (millisieverts/megabecquerel \[mSv/MBq\]) for regions of the whole body. Target organs included the adrenals, brain, breasts, gall bladder wall, lower large intestine wall, small intestine wall, stomach wall, upper large intestine wall, heart wall, kidneys, liver, lungs, muscle, ovaries, pancreas, osteogenic cells, skin, spleen, testes, thymus, thyroid, urinary bladder wall, uterus, and total body.
Interventions
- DRUG florbetapir F 18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
What the finished NCT01564706 record still lists
NCT01564706 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which florbetapir F 18 is the first listed.
NCT01564706 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01564706 about?
NCT01564706 is a clinical study titled "A Study of 18F-AV-45 in Healthy Volunteers". This study will determine how florbetapir F 18 (18F-AV-45) radioactivity is distributed throughout the body.
What is the current status of trial NCT01564706?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2007-10. Estimated completion is 2008-01.
What interventions are being tested in trial NCT01564706?
The interventions under investigation include: florbetapir F 18 (DRUG).
Who is sponsoring clinical trial NCT01564706?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01564706's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia